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Abstract: A 65-year-old lady presented with decreased vision in her left eye (LE). Best corrected 
visual acuity (BCVA) was 1/20. Complete examination showed idiopathic juxtafoveal retinal 
telangiectasis associated with subretinal neovascularization and she was treated with intravitreal 
ranibizumab every month for three months in the LE. After four months, her BCVA increased to 
3/10. Fluorescein angiography (FA) showed minimal leakage and optical coherence tomography 
(OCT) conﬁ  rmed absence of intra- or subretinal ﬂ  uid in the macula. Examinations were repeated 
monthly for another 12 months and showed no recurrence. Intravitreal ranibizumab showed 
promising results for subretinal neovascularization due to idiopathic juxtafoveal retinal telan-
giectasis. A prospective study with large series of patients and controls may be necessary in 
order to determine the effectiveness of this treatment.
Keywords: idiopathic juxtafoveal retinal telangiectasis, ranibizumab, subretinal 
neovascularization
Introduction
Gass and Blodi1 deﬁ  ned bilateral acquired retinal telangiectasis or perifoveal telan-
giectasia or type 2A telangiectasis as a rare retinal disease characterized by retinal 
thickening temporal to the fovea, right-angle venules, retinal pigment epithelial (RPE) 
hyperplastic plaques, and crystalline deposits. Bilateral acquired retinal telangiectasis 
can be divided into ﬁ  ve stages. The disease is usually becoming symptomatic through 
the sixth decade of life when complicated by subretinal neovascularization which is 
localized mostly subfoveally in stage 5 of the disease.1–3
We report the outcome of treatment with 0.5 mg intravitreal ranibizumab in a 
patient with a subretinal neovascular membrane secondary to idiopathic juxtafoveal 
retinal telangiectasis.
Case history
A 65-year-old Caucasian lady presented to our clinic complaining of decreased vision 
in her left eye (LE). On presentation, best-corrected visual acuity (BCVA) was 10/10 
in the right eye (RE) and 1/20 LE. Anterior segment examination was unremarkable in 
both eyes and intraocular pressures were within normal limits. Fundus biomicroscopy 
revealed in the right macula, slightly dilated right-angle veins with RPE hyperplasia 
beneath them (Figure 1A). In addition to these ﬁ  ndings, in the left macula there was 
subretinal hemorrhage (Figure 1B). The clinical appearance of the macular area 
of the LE was consistent with idiopathic juxtafoveal retinal telangiectasis compli-
cated by subretinal neovascularization. Fluorescein angiography (FA) and optical 
coherence tomography (OCT) were performed and conﬁ  rmed the above diagnosis 
(Figures 1C–D, 2, 3A). OCT of the LE revealed the characteristic appearance of outer 
and inner retina having similar reﬂ  ectivity and an area temporal to the fovea with high Clinical Interventions in Aging 2009:4 64
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reﬂ  ectivity corresponding to the temporal area of choroidal 
neovascularization (CNV) (Figure 3A), which was observed 
in the angiogram. After a discussion outlining the possible 
risks and beneﬁ  ts of the treatment, the patient was started 
on 0.5 mg intravitreal ranibizumab in the LE. Based on the 
ﬁ  ndings of FA and OCT which were performed monthly, the 
patient underwent three intravitreal injections of ranibizumab 
every month for three months. Following these injections, 
BCVA increased to 3/10 and both clinical and angiographic 
appearances showed signiﬁ  cant improvement with minimal 
leakage in FA and absence of intra- or subretinal ﬂ  uid in 
OCT and signiﬁ  cant reduction in retinal thickness; the RPE 
remained thickened (Figures 3B, 4A–B). Examinations 
were repeated monthly for another 12 months and showed 
no recurrence of CNV.
Discussion
Bilateral acquired retinal telangiectasis or retinal 
telangiectasis type 2A, according to Gass and Blodi, 
or type 2 perifoveal telangiectasia according to the 
classification by Yannuzzi is a symmetrical disease.1,3 
The area involved is usually less than a disc diameter 
and is typically temporal to the fovea.1 Gas and Blodi 
divided the development of group 2A telangiectasis into 
five stages.1 Stage 1 is found on FA on the asymptomatic 
fellow eye as staining at the level of the RPE. Stage 2 
is characterized by the loss of transparency of the retina 
near the fovea and visible telangiectasis only in FA. 
In stage 3, FA shows capillary dilatation and staining. 
Stage 4 reveals migrating RPE cells appearing as stellate 
foci along the right-angle venules. Stage 5, according to 
Gass and Blodi, or the proliferative stage according to 
Figure 1A) Right eye: Color fundus picture showing slightly dilated right-angle 
veins with retinal pigment epithelium hyperplasia beneath them. B)  Left eye: Color 
fundus picture showing subretinal hemorrhage inferior and temporal to the fovea. 
C)   Venous phase of FA of the LE depicts early hyperﬂ  uorescence corresponding to 
the neovascular membrane and hypoﬂ  uorescence inferior to the membrane corre-
sponding to the subretinal hemorrhage. D)  Late phase of FA showing leakage from 
the neovascular membrane.
Abbreviations: FA, ﬂ  uorescein angiography; LE, left eye; OCT, optical 
coherence tomography.
Figure 2 Oblique section of OCT of the LE.
Abbreviations: LE, left eye; OCT, optical coherence tomography.
Figure 3A) Oblique section of OCT of the LE revealing the characteristic 
appearance of outer and inner retina having similar reﬂ  ectivity and an area temporal 
to the fovea with high reﬂ  ectivity corresponding to the temporal area of choroidal 
neovascularization observed in the angiogram. B) OCT of the same section of LE 
revealing signiﬁ  cant reduction in retinal thickness. The RPE remains thickened.
Abbreviations: LE, left eye; OCT, optical coherence tomography; RPE, retinal 
pigment epithelium.
Figure 4 A) Left eye: Color fundus picture following ranibizumab treatment reveal-
ing signiﬁ  cant improvement with no subretinal hemorrhage. B) late venous phase 
of FA of the LE showing minimal leakage due to telangiectasis but no signs of active 
neovascular membrane.
Abbreviations: FA, ﬂ  uorescein angiography; LE, left eye.Clinical Interventions in Aging 2009:4 65
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Yannuzzi’s classification of the disease, is associated with 
subretinal neovascularization.1,3
According to Engelbrecht and colleagues2 the natural 
course of the disease in stage 5 is not good in 80% of cases, 
resulting to visual acuity of 1/20 or less.
Snyers and colleagues showed that from four patients 
treated with photodynamic therapy (PDT), three of those 
retained their visual acuity, however, there was no signiﬁ  cant 
improvement.4
Vascular endothelial growth factor (VEGF) is a major 
key player for angiogenesis in the eye in several physiologic 
and pathologic conditions. Concerning anti-VEGF therapy 
in ocular disease, clinical trials with ranibizumab show a 
beneﬁ  cial effect for all subtypes of CNV including diseases 
such as pathological myopia and age-related macular degen-
eration. In addition, anti-VEGF therapy showed beneﬁ  cial 
results, both clinically and anatomically, for idiopathic macu-
lar telangiectasia which was not associated with subretinal 
neovascularization.5
Recently, Ruys and colleagues have reported that the 
intravitreal delivery of bevacizumab (Avastin), with or 
without PDT was beneﬁ  cial for both anatomical and visual 
outcome for subretinal neovascularization due to idiopathic 
juxtafoveal retinal telangiectasis.6 Other reports also support 
this beneﬁ  cial outcome of bevacizumab (Avastin) (Table 1).7–9 
In most of these cases the neovascularization ceased after two 
injections of bevacizumab.7
Also, combined PDT and intravitreal ranibizumab 
appears to be efﬁ  cacious in the treatment of subretinal neo-
vascularization associated with proliferative type 2 idiopathic 
macular telangiectasia (Table 1).10
In our case we chose to use ranibizumab since it 
has been designed for intraocular use; three intravitreal 
applications of ranibizumab, repeated monthly, alone 
without any additional session of PDT, were sufﬁ  cient to 
cease the neovascularization during a follow-up time of 
12 months.
In conclusion, intravitreal ranibizumab seems to have 
favorable results in the treatment of subretinal neovasculariza-
tion due to idiopathic juxtafoveal retinal telangiectasis. Further 
studies are required to evaluate the above ﬁ  ndings, although 
the implementation of large-series studies remains a challenge 
due to the rarity of cases with subretinal neovascularization 
secondary to idiopathic juxtafoveal retinal telangiectasis.
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Table 1 Anti-VEGF for the treatment of subretinal neovascular membrane associated with type 2 idiopathic macular telangiectasia: 
Summarized review of the literature
Author publication Patients Anti-VEGF PDT Follow-up (months) Year of publication
Rishi et al10 1 Ranibizumab Yes 16 2008
Mandal et al7 6 Bevacizumab No 3–6 2008
Jorge et al8 1 Bevacizumab No 24 2008
Ruys et al6 2 Bevacizumab Case 1: Yes Case 2: No 1–3 2007
Moon et al9 1 Bevacizumab No 3 2007
Abbreviations: PDT, photodynamic therapy;  VEGF, vascular endothelial growth factor.